WO2024001530A1 - Utilisation d'une combinaison d'un lymphocyte t activé et d'un anticorps bloquant dans la préparation d'un médicament antitumoral, et médicament antitumoral - Google Patents

Utilisation d'une combinaison d'un lymphocyte t activé et d'un anticorps bloquant dans la préparation d'un médicament antitumoral, et médicament antitumoral Download PDF

Info

Publication number
WO2024001530A1
WO2024001530A1 PCT/CN2023/092933 CN2023092933W WO2024001530A1 WO 2024001530 A1 WO2024001530 A1 WO 2024001530A1 CN 2023092933 W CN2023092933 W CN 2023092933W WO 2024001530 A1 WO2024001530 A1 WO 2024001530A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
human
antibody
activated
antibodies
Prior art date
Application number
PCT/CN2023/092933
Other languages
English (en)
Chinese (zh)
Inventor
邱晓彦
范天睿
何峙峤
Original Assignee
北京艾赛吉生物医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京艾赛吉生物医药科技有限公司 filed Critical 北京艾赛吉生物医药科技有限公司
Publication of WO2024001530A1 publication Critical patent/WO2024001530A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Definitions

  • the present invention relates to the technical field of tumor immunotherapy, and specifically to the use of activated T cells and blocking antibodies to prepare anti-tumor drugs and anti-tumor drugs.
  • T cells for tumor immunotherapy has made clinical breakthroughs.
  • the main treatment idea is to activate T cells through genetic engineering technology and install them with a positioning navigation device CAR (tumor chimeric antigen receptor) to become CAR-T Cells, this kind of T cells use their "positioning navigation device" CAR to specifically identify tumor cells in the body, and kill tumor cells through direct immune killing and release a large number of various effectors to achieve the purpose of treating malignant tumors.
  • CAR tumor chimeric antigen receptor
  • the purpose of the present invention is to address the above-mentioned problems in the prior art and provide a method for combining activated T cells and blocking antibodies to prepare anti-tumor drugs and an anti-tumor drug.
  • the present invention provides the use of activated T cells and blocking antibodies to prepare anti-tumor drugs.
  • the activated T cells are obtained by separating cells from the patient's own tissues or body fluids and first sorting anti-human CD3 antibodies.
  • CD3 + T cells are obtained through stimulation and activation by anti-human CD3 antibodies, anti-human CD28 antibodies and human IL-2;
  • the blocking antibodies are antibodies against sialylated IgG (SIA-IgG) produced by human cancer cells, and anti- Any one or more of human Siglec-7 antibody, anti-human Siglec-9 antibody, anti-human Siglec-10 antibody and anti-human PD-1 antibody.
  • the tissue is cancer tissue
  • the body fluid is peripheral blood, pleural effusion or ascites.
  • pleural effusion and ascites are larger in volume than cancer tissue and peripheral blood, and are wastes that are easier to obtain for patients, they are more suitable body fluid materials for clinical applications.
  • the preparation method of activated T cells is as follows:
  • the patient's pleural fluid or ascites is centrifuged to obtain cell pellets. After the cell pellets are washed with PBS, primary humoral cells are separated by density gradient centrifugation. The primary humoral cells are centrifuged with human lymphocyte separation medium to obtain humoral cells;
  • Humoral cells were incubated with anti-human CD3 antibody in the dark, then washed once with PBS and resuspended in 1% (v/v) FBS In PBS, CD3 + T cells were sorted using a flow sorter;
  • Anti-human CD3 antibody, anti-human CD28 antibody and human IL-2 are added to the CD3 + T cell culture system to stimulate and induce culture to obtain activated T cells.
  • the primary humoral cells and humoral cells are only used for descriptive purposes and represent cells obtained after density gradient centrifugation or cells separated by human lymphocyte separation fluid. They are not words with specific medical or biological meanings.
  • PBS stands for Phosphate Buffered Saline
  • FBS stands for Fetal Bovine Serum.
  • the CD3 + T cells obtained by sorting are CD3 + 7AAD - T cells.
  • 7AAD is a classic nucleic acid labeling dye that can be used to label dead cells in flow cytometry.
  • the above-mentioned CD3 + 7AAD - T cells are viable T cells that are negative (not stained) after being stained with 7AAD.
  • the anti-sialylated IgG antibody produced by human cancer cells is RP215 or an anti-SIA-IgG humanized antibody, and the heavy chain of the anti-SIA-IgG humanized antibody is variable.
  • the amino acid sequence of the region is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2.
  • RP215 is a mouse anti-human monoclonal antibody selected by Professor Gregory Lee from the ovarian cancer cell line OC-3-VGH. In the past, its corresponding antigen was believed to be CA215, which contains IgG expressed by human cancer cells and also contains Other glycoproteins. Preliminary studies by the inventor of the present invention have confirmed that the recognition antigen of RP215 is actually an IgG with a unique N-glycosylation modification at position 162 of the CH 1 region expressed by human cancer cells and a hypersialylation modification at the end of the sugar chain. RP215 can be obtained by requesting a gift or purchasing it.
  • the present invention also provides an anti-tumor drug, which includes activated T cells and blocking antibodies.
  • the activated T cells are cells isolated from the patient's own tissues or body fluids, and anti-human CD3 antibodies are first analyzed. CD3 + T cells are selected and then stimulated and activated by anti-human CD3 antibodies, anti-CD28 antibodies and human IL-2; the blocking antibodies are antibodies against sialylated IgG (SIA-IgG) produced by human cancer cells, Any one or more of anti-human Siglec-7 antibody, anti-human Siglec-9 antibody, anti-human Siglec-10 antibody and anti-human PD-1 antibody.
  • the tissue is cancer tissue
  • the body fluid is peripheral blood, pleural effusion or ascites.
  • the preparation method of activated T cells is as follows:
  • the patient's pleural fluid or ascites is centrifuged to obtain cell pellets. After the cell pellets are washed with PBS, primary humoral cells are separated by density gradient centrifugation. The primary humoral cells are centrifuged with human lymphocyte separation medium to obtain humoral cells;
  • Body fluid cells were incubated with anti-human CD3 antibodies in the dark, then washed once with PBS and resuspended in PBS containing 1% (v/v) FBS, and CD3 + T cells were sorted using a flow sorter;
  • Anti - human CD3 antibody, anti-CD28 antibody and human IL-2 are added to CD3 + T cells to stimulate and induce culture to obtain activated T cells.
  • the anti-sialylated IgG antibody produced by human cancer cells is RP215 or an anti-SIA-IgG humanized antibody, and the heavy chain of the anti-SIA-IgG humanized antibody is variable.
  • the amino acid sequence of the region is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2.
  • CD3 Cluster of differentiation 3, a transmembrane protein whose transmembrane region is connected to the transmembrane regions of two peptide chains of TCR (T cell receptor, T cell antigen receptor) through a salt bridge to form a TCR-CD3 complex. Together, they participate in T cell recognition of antigens.
  • Anti-human CD3 antibody can specifically recognize and bind to CD3, which is a T cell antigen receptor.
  • CD28 is leukocyte surface differentiation antigen 28. Anti-human CD28 antibody can specifically recognize and bind to CD28, which is a T cell antigen receptor.
  • Sialylated IgG produced by human cancer cells namely SIA-IgG and Sialylated-IgG
  • SIA-IgG is an IgG with unique N-glycosylation modification at position 162 in the CH 1 region of the constant region and hypersialylation modification at the end of the sugar chain. It is expressed in cancer cells surface.
  • this IgG can bind to Singles on the surface of tumor-infiltrating T cells, causing T cell activation and proliferation to be inhibited, and the T cells lose their ability to kill tumors.
  • Anti-SIA-IgG antibodies can block the proliferation inhibitory effect of SIA-IgG on Siglec downstream signaling.
  • Siglec sialic acid binding Ig-like lectins, sialic acid-binding Ig-like lectins, can bind to the immunosuppressive receptor sialic acid on the surface of T cells.
  • Siglec is a single-pass transmembrane protein, consisting of an extracellular segment containing a sialic acid-binding site, a transmembrane region, and an intracellular segment that transmits signals.
  • 15 human Siglec molecules have been discovered.
  • Siglec family is divided into two categories: one is Siglecs with conserved sequences, including sialyadhesin (Siglec-1), CD22 (Siglec-2), CD33 (Siglec-3), MAG (Siglec-4) and Siglec-15; the other type is sequence-variable Siglecs related to CD33.
  • Siglec-7, Siglec-9 and Siglec-10 are often constitutively expressed on the surface of T cells in tumor patients. After binding to SIA-IgG on the surface of tumor cells, they obtain a proliferation inhibitory signal, resulting in their inability to kill tumor cells.
  • anti-Siglec-7 antibody, anti-Siglec-9 antibody and anti-Siglec-10 antibody alone or the combination of the above three anti-Siglec antibodies can block the binding of SIA-IgG to Siglec, thus blocking the downstream signal of Siglec by SIA-IgG and activating T Cell-killing tumor effect.
  • PD-1 programmed death 1
  • programmed death receptor 1 is also an inhibitory molecule (immune checkpoint molecule) on the surface of T cells in tumor patients, inducing an inhibitory effect on T cell proliferation.
  • Anti-PD-1 antibodies can block the inhibition of PD-1 Proliferation inhibitory signal enhances T cell tumor killing ability.
  • the present invention has the following beneficial effects:
  • CD3 molecules are unique molecular markers for T cells.
  • anti-human CD3 antibodies are used to label T cells, and then flow cytometry is used to sort and purify T cells from blood, pleural fluid, ascites, etc., because T cells need to kill tumors.
  • T cells change from an inactive state to an activated state, and anti-human CD3 antibodies can induce the first activation signal of T cells, anti-human CD28 Antibodies can induce the second activation signal of T cells, and IL-2 can activate the third signal of T cells by binding to its specific receptor on the surface of T cells.
  • activated T cells are not limited to the above three substances.
  • antigens and cytokines such as IL-4, IL-7, IL-15, IL-21, IL-18, IFN- ⁇ , TNF (tumor necrosis factor) , GMCSF (Granulocyte Macrophage Colony Stimulating Factor), CD70, GlyCAM-1, CD34, MadCAM-1, PSGL-1, etc.
  • TNF tumor necrosis factor
  • GMCSF GMCSF (Granulocyte Macrophage Colony Stimulating Factor)
  • CD70 CD34
  • MadCAM-1 MadCAM-1
  • PSGL-1 a large number of experiments, the invention found that using anti-human CD3 antibodies, anti-human CD28 antibodies and IL-2 for combined stimulation and induction is a combination method that activates T cells and has anti-tumor functions at the lowest cost and is suitable for clinical application.
  • the present invention combines activated T cells obtained through stimulation and activation in a specific way with specific blocking antibodies.
  • the two can produce a synergistic effect, more efficiently promote the killing effect of T cells, induce tumor cell apoptosis, and improve the therapeutic effect.
  • activated T cells can be obtained from the patient's own blood and wastes such as pleural effusion and ascites.
  • the isolation and activation process is simple to operate, requires low technical requirements for operators, and is low-cost, making it very suitable for large-scale clinical promotion.
  • Figure 1 is a layered schematic diagram of mononuclear cells separated using a lymphocyte separation solution in Example 1.
  • Figure 2 shows the detection of CD4 + T cells using flow cytometry at different times after induction and activation using T cells isolated from normal peripheral blood in Example 1.
  • CD8 + T cells express CD25, Siglec-7 and TIM-3 (immune checkpoint molecule) ratio.
  • Figure 3 shows the expression of CD25 (T cell activation marker molecule) and Siglec-7 by CD4 + T cells and CD8 + T cells after T cells isolated from colon cancer were activated with anti-CD3 and anti-CD28 antibodies and IL-2 in Example 1. and the ratio of T cell immune checkpoint molecules PD-1, LAG-3 and TIM-3.
  • Figure 4 shows the expression of Siglec-7, Siglec-10 and T cell immune checkpoint molecules PD-1 and TIM after T cells isolated from ovarian cancer ascites fluid were activated with anti-CD3 and anti-CD28 antibodies and IL-2 in Example 1.
  • -3 Expression frequency and level A is a picture of the proliferation status of T cells isolated from ascites after adding different reagents for 96 hours of incubation. The left picture was added with PBS, and the right picture was added with anti-CD3 and anti-CD28 antibodies and IL-2; B is the CD4 + after 96 hours.
  • CD25 marker molecule for T cell activation
  • Siglec-7 represents unactivated T cells
  • ⁇ CD3/CN28+IL- 2 indicates activated T cells. Measurement results are expressed as mean ⁇ standard deviation. **P ⁇ 0.01, ***P ⁇ 0.001, ****P ⁇ 0.0001; ns, not significant (P>0.05).
  • Figure 5 shows the difference in cell activation ability and expression of Siglec-9, Siglec-10, PD-1 and LAG-3 after sorting Siglec-7 + and Siglec- 7- T cells from ovarian cancer ascites in Example 1,
  • A are the folds of cell growth in each well.
  • B, C, D, and E are flow cytometric detection of Siglec-7 + and Siglec-7 - T cells expressing PD-1, LAG-3, Siglec-9, and Siglec-10 respectively after activation. proportion. Measurement results are expressed as mean ⁇ standard deviation. **P ⁇ 0.01, **P ⁇ 0.001.
  • Figure 6 is the experimental results of Example 2 for detecting the expression of SIA-IgG by tumor cells in ovarian cancer ascites.
  • A is flow cytometry staining of ovarian cancer ascites tumor cells using RP215, and the gate shows the RP215-positive cell group and proportion;
  • B This is the result of immunofluorescence staining (green light) of ovarian cancer ascites films using RP215.
  • Figure 7 is a flow cytometric analysis of the apoptosis of EpCAM + tumor cells in Example 2 after adding activated or non-activated T cells to the co-culture system of activated T cells and ovarian cancer cells derived from the same individual. Apoptotic tumor cells are stained for EpCAM + AnnexinV + 7AAD + .
  • Figure 8 shows the ratio of tumor cell apoptosis detected by co-culture with tumor cells after T cells purified from the ascites of ovarian cancer in Cases 1-4 were activated by anti-CD3, anti-CD28 antibodies and IL-2 in Example 2. Ovarian cancer cells from the same individual were added to the activated T cell culture system respectively. After co-culture for 24 hours, the proportion of AnnexinV + 7AAD + late apoptotic cells in EpCAM + tumor cells was measured by flow cytometry. The measurement results are expressed as mean ⁇ Standard deviation means, *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001, ****P ⁇ 0.0001.
  • Figure 9 shows that T cells purified from the ascites of ovarian cancer in Cases 5-6 in Example 2 were activated by anti-CD3, anti-CD28 antibodies and IL-2 and co-cultured with tumor cells derived from the same individual. EpCAM + tumors were detected by flow cytometry 24 hours later. Statistical results of the proportion of AnnexinV + 7AAD + late apoptotic cells in cells; measurement results are expressed as mean ⁇ standard deviation, *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001, ****P ⁇ 0.0001.
  • Figure 10 is the statistical result of detecting the proportion of 7AAD + late-stage apoptotic tumor cells in the co-culture system of tumor cells purified from ovarian cancer ascites fluid and non-activated T cells in 2.4 of Example 2 after adding different antibodies respectively.
  • the T cells are Unactivated T cells, Ab includes anti-human CD3 antibody, anti-human CD28 antibody and recombinant human IL-2, ⁇ Sig-7 is anti-Siglec-7 antibody, ⁇ PD-1 is anti-PD-1 antibody, mIgG is mouse IgG; measurement The results are expressed as mean ⁇ standard deviation, *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001, ****P ⁇ 0.0001.
  • Figure 11 shows the ovarian cancer PDX model constructed subcutaneously in nude mice in Example 3. After tumor formation, T cells purified and activated from ovarian cancer ascites fluid were used, and the activated T cells were treated with Siglec-7 blocking, and the activity of activated T cells was analyzed. Experimental process and result diagram of anti-tumor effect.
  • A is a schematic diagram of establishing the OAC-E ovarian cancer tumor model in nude mice; B is the comparison of ovarian cancer tumor volumes in each group of mice on the 26th day; C is the growth curve of the ovarian cancer tumors in each group of mice; D is the 26th day Statistical comparison of the volume and mass of ovarian cancer tumors in mice in each group; E is the percentage of CD4 + T cells and CD8 + T cells in the ovarian cancer tumors of mice in each group on day 26. Measurement results are expressed as mean ⁇ standard deviation, *P ⁇ 0.05, **P ⁇ 0.01, ns, not significant (P>0.05).
  • F is the result of HE staining of ovarian cancer tumors of mice in each group, scale bar: 50 ⁇ m.
  • Figure 12 is a diagram showing the experimental process and results of Embodiment 3 of constructing an ovarian cancer PDX model subcutaneously in NOD-SCID mice and analyzing the anti-tumor effect of blocking SIA-IgG/Siglec-7 to enhance T cells.
  • mice were divided into 5 groups, namely PBS group (control group), activated T cells alone group, RP215 alone group, activated T cells plus SIA-IgG and activated T cells. cells plus anti-Siglec-7 antibody group.
  • A is a schematic diagram of establishing the OAC-E ovarian cancer tumor model in NOD-SCID mice; B is the comparison of ovarian cancer tumor volumes in each group of mice on day 29; C is the growth curve of ovarian cancer tumors in each group of mice; D is Statistical comparison of the volume and mass of ovarian cancer tumors in each group of mice on day 29; E is the percentage of CD4 + T cells and CD8 + T cells in the ovarian cancer tumors of mice in each group on day 29. The measurement results are expressed as mean ⁇ standard deviation, *P ⁇ 0.05, **P ⁇ 0.01, ns, not significant (P>0.05); F is the result of HE staining of ovarian cancer tumors of mice in each group. Scale bar: 50 ⁇ m.
  • PBMC mononuclear cells
  • the liquid in the centrifuge tube will be divided into three layers, the upper layer is PBS, the middle layer is lymphocyte stratification fluid, the white cloudy cell layer between the upper layer and the middle layer is PBMC, and the lower layer is granulocytes and red blood cells, as shown in Figure 1. Show. Carefully remove the cells from the PBMC layer, wash them with a large volume of PBS and then count them.
  • the ascites obtained from ovarian cancer patients was centrifuged at 2000 rpm to obtain cell pellets. After washing twice with large volume of PBS, use density gradient centrifugation to separate cells from ascites. The subsequent steps are the same as the separation of human peripheral blood mononuclear cells in 1.1.1.
  • Peripheral blood PBMC, colon cancer tissue cell suspension or ovarian cancer ascites cell suspension were resuspended in PBS containing 5% FBS, and allowed to stand on ice for 30 minutes to block. Centrifuge and discard the supernatant, add an appropriate dose of fluorescently labeled anti-human CD3 antibody, dilute the antibody with 500 ⁇ L 1% FBS in PBS (5 ⁇ L/10 7 cells), and incubate at 4°C in the dark for 30 min; wash once with 1 ml PBS and resuspend. Add 200 to 400 ⁇ L of 1% FBS in PBS and place on ice to protect from light until use. Use a BD FACSMelody flow sorter for sorting. Add 7AAD (5 ⁇ L/10 7 cells) 5 minutes before sorting to sort CD3 + 7AAD - T cells.
  • the cell density of the 96-well plate is 2 ⁇ 10 5 /well, and the culture medium volume is 200 ⁇ L; the 48-well plate density is 4 ⁇ 10 5 /well, the culture medium volume is 400 ⁇ L, and the activated T cells are obtained after culturing for 96 hours.
  • the anti-human CD3 antibody, anti-human CD28 antibody, and IL-2 were replaced with equal concentrations and doses of PBS, and the obtained T cells were used as negative controls for unactivated T cells.
  • the above-mentioned activated T cells and non-activated T cells were subjected to flow cytometric detection of direct immunofluorescence-labeled antibodies.
  • Flow cytometry detection method Prepare the cells to be detected as a single cell suspension. After washing once with PBS (pH 7.2), use PBS containing 5% (v/v) FBS and let stand on ice for 30 minutes for blocking. Centrifuge and discard the supernatant, add appropriate doses of fluorescently labeled antibodies to different membrane molecules, dilute the antibodies with 50 ⁇ L of 1% (v/v) FBS in PBS (0.1 to 0.3 ⁇ L/sample), and incubate in the dark at 4°C for 30 min; 1 mL of PBS Wash once, resuspend in 200-400 ⁇ L 1% (v/v) FBS in PBS and keep on ice to protect from light until use.
  • Fluorescence signals were detected using a BD FACSCantoplus flow cytometer or a BD FACSVerse flow cytometer.
  • the cells in each group should not exceed 5 ⁇ 10 6 /mL, and the centrifugal speed should be 5,000rpm; for tumor cells, each group should not exceed 5 ⁇ 10 5 /mL, and the centrifugal speed should be 3,500rpm.
  • Anti-human CD3 antibody, anti-human CD28 antibody and human IL-2 were added for stimulation and activation at different times, and the proportions of CD4 + T cells and CD8 + T cells expressing CD25, Siglec-7 and TIM-3 were detected.
  • T cells in peripheral blood expressed CD25, Siglec-7 and TIM-3.
  • the levels of molecules are all low.
  • the expression of CD25 on T cells was significantly increased, indicating that the stimulation and activation was successful, see Figure 2.
  • CD4 + T cells both Siglec-7 and TIM-3 were upregulated to a lesser extent.
  • CD8 + T cells the upregulation of Siglec-7 and TIM-3 is more obvious, and the positive proportion of Siglec-7 can reach more than 40% at 48 hours.
  • CD4 + T cells were detected.
  • CD8 + T cells expressed CD25, PD-1, Siglec-7, TIM-3 and LAG. -3 ratio.
  • CD4 + T cells of colon cancer about 20% of LAG-3 and Siglec-7 were positively expressed when not stimulated, and the positive rates of other molecules were lower; as the cells were stimulated and activated, CD25, Siglec -7, PD-1, LAG-3 and other molecules were significantly up-regulated, but TIM-3 was not significantly up-regulated, see Figure 3.
  • CD8 + T cells express up to PD-1 (60%) and Siglec-7 at a low frequency (about 10%) under unstimulated conditions, while other detected molecules are less than 5%; after T cell activation, PD Although -1 was slightly down-regulated at 24 hours, it returned to a higher expression level at 72 hours.
  • CD25, LAG-3 and Siglec-7 were all significantly up-regulated, and TIM-3 was also slightly up-regulated.
  • the level of T cells expressing molecules in the tumor microenvironment is very different from that in peripheral blood in the resting state, but after being stimulated and activated by anti-human CD3 antibodies, anti-human CD28 antibodies and human IL-2, their Siglec-7 and other immune checkpoint molecules were up-regulated in the same direction.
  • the fluorescently labeled antibodies added during the flow cytometry detection process are: anti-CD25 antibody (as a marker of T cell activation), anti-PD-1 antibody (detection of immune checkpoint molecules), and anti-TIM-3 antibody (detection of immune checkpoint molecules). ), anti-Siglec-7 antibody, anti-Siglec-10 antibody and anti-CD4 antibody (detection of CD4 + T cells) and anti-CD8 antibody (detection of CD8 + T cells).
  • the detection results 96 hours after induction and activation are shown in Figure 4.
  • the activation-related molecules CD25, immune checkpoint molecules PD-1, TIM-3 and Siglec in CD4 + T cells -7, Siglec-10 and other molecules were significantly up-regulated, among which the expression of Siglec-7 was the most obvious.
  • CD8 + T cells the expression levels of PD-1, Siglec-7, and Siglec-10 are slightly lower than those of CD4 + T cells, but compared with unactivated T cells, there is a similar upregulation after activation, and TIM-3 There are no significant changes.
  • Siglec-7 + and Siglec-7 - T cells from ovarian cancer ascites, plated them at 5000 cells per well, and used anti-human CD3/ CD28 antibody + human IL-2 was activated, and 48 hours later the difference in proliferation folds of the two cells and the difference in expression molecules were detected.
  • Siglec-7 + T cells showed obvious proliferation inhibition, and the increase in cell number after stimulation and activation was only 2-3 times, while Sigecle-7 - T cells could proliferate more than 10 times (Figure 5 A).
  • Siglec-7 + CD8 + T cells expressed higher levels of immune checkpoint molecules PD-1 and LAG-3, suggesting that their functions after activation are in a more inhibited state ( Figure 5, B and C).
  • Siglec-7 + CD8 + T cells also expressed more inhibitory Siglec molecules such as Siglec-9 and Siglec-10 (D, E in Figure 5).
  • T cells expressing Siglec-7 are in a more suppressive state, showing lower proliferation ability and higher levels of expression of immunosuppressive molecules.
  • T cells in ovarian cancer ascites express higher levels of Siglec molecules. And it contains a large number of tumor cells and immune cells, allowing us to obtain enough cells for experiments. Therefore, we first selected ovarian cancer ascites, sorted the T cells and tumor cells respectively, and constructed an in vitro co-culture model.
  • anti-human CD3 antibodies, anti-human CD28 antibodies and recombinant human interleukin-2 (IL-2) were added in vitro for activation and culture.
  • Activated T cells were obtained after 48 hours of stimulation-induced activation; unactivated T cells were obtained by culturing T cells induced by stimulation without the addition of two antibodies and IL-2 for the same period of time (as a control).
  • AnnexinV and 7AAD staining were used to detect the proportion of AnnexinV + 7AAD + late apoptotic cells in EpCAM + tumor cells by flow cytometry.
  • Anti-SIA-IgG antibodies and anti-Siglec-7 antibodies can enhance the killing effect of activated T cells on tumor cells
  • blocking antibodies anti-SIA-IgG antibodies and anti-Siglec-7 antibodies could enhance the killing effect of activated T cells on tumor cells in the successfully established in vitro co-culture model.
  • Tumor cells obtained by EpCAM + sorting from ovarian cancer ascites from different cases were used to conduct co-culture experiments of activated T cells and tumor cells.
  • the ratio of tumor cells to T cells was 4:1.
  • Co-cultured cells from the same case were divided into five groups:
  • T (unactivated) group tumor cells are added with unactivated T cells as a negative control;
  • T (activated) group tumor cells are added to activated T cells;
  • T (activated) + RP215 group activated T cells and RP215 are added to tumor cells;
  • T (activated) + anti-Sig7 group tumor cells are added with activated T cells and mouse anti-Siglec-7 antibody;
  • T (activated) + mouse IgG group tumor cells were added with activated T cells and mouse IgG as a control mIgG group.
  • T (activated)+RP215+anti-Sig7 group tumor cells were added with activated T cells, RP215, and mouse anti-human Siglec-7 antibody.
  • the dosages of unactivated T cells and activated T cells are the same.
  • the dosages of RP215, mouse anti-human Siglec-7 antibody, and mouse IgG are the same, and their final concentrations in the entire culture system are Both were 10 ⁇ g/mL, and the final concentrations of RP215 and mouse anti-Siglec-7 antibodies in case 4 were 5 ⁇ g/mL each, totaling 10 ⁇ g/mL).
  • the proportion of AnnexinV + 7AAD + late apoptotic cells in EpCAM + tumor cells was detected by flow cytometry, reflecting the killing effect of T cells.
  • Anti-Siglec-7 antibodies, anti-Siglec-9 antibodies, and anti-Siglec-10 antibodies can enhance the killing effect of activated T cells on tumor cells
  • Tumor cells obtained by EpCAM + sorting from ovarian cancer ascites from different cases were used to conduct co-culture experiments of activated T cells and tumor cells. Co-cultured cells from the same case were divided into six groups:
  • T (unactivated) group tumor cells are added to unactivated T cells;
  • T (activated) group tumor cells are added to activated T cells;
  • T (activated) + anti-Sig7 group tumor cells were added with activated T cells and goat anti-Siglec-7 antibody;
  • T (activated) + anti-Sig9 group tumor cells were added with activated T cells and goat anti-Siglec-9 antibody;
  • T (activated) + anti-Sig10 group tumor cells were added with activated T cells and goat anti-Siglec-10 antibody;
  • T (activated) + goat IgG group tumor cells were added with activated T cells and goat IgG.
  • the dosages of unactivated T cells and activated T cells are the same, and the dosages of goat anti-Siglec-7 antibody, goat anti-Siglec-9 antibody, goat anti-Siglec-10 antibody, and goat IgG are the same (the final concentration in the culture system is 10 ⁇ g/ mL).
  • the proportion of AnnexinV + 7AAD + late apoptotic cells in EpCAM + tumor cells was detected by flow cytometry after 24 hours of co-culture.
  • CD3 + 7AAD - T cells were sorted from ovarian cancer ascites using anti-human CD3 antibodies and 7AAD, which were unactivated T cells.
  • Tumor cells were sorted from ovarian cancer ascites using anti-human EpCAM antibodies.
  • Tumor cells and T cells were co-cultured in vitro at a ratio of 4:1.
  • the co-culture system is divided into eight groups:
  • Tumor cells + T cells (PBS) group Tumor cells are co-cultured with unactivated T cells, and PBS (the same volume as the PBS used to dilute antibodies and IL-2 in the following groups) is added as a negative control;
  • Tumor cell + T cell (Ab) group tumor cells and unactivated T cells are co-cultured, and PBS containing anti-human CD3 antibody, anti-human CD28 antibody, and recombinant human IL-2 is added;
  • Tumor cells + T cells (Ab + RP215) group: tumor cells and unactivated T cells were co-cultured, and PBS containing anti-human CD3 antibody, anti-human CD28 antibody, recombinant human IL-2 and RP215 was added;
  • Tumor cells + T cells (Ab + ⁇ Sig-7) group: tumor cells and unactivated T cells were co-cultured, and PBS containing anti-human CD3 antibodies, anti-human CD28 antibodies, recombinant human IL-2 and anti-Siglec-7 antibodies was added;
  • Tumor cells + T cells (Ab + ⁇ PD-1) group tumor cells and unactivated T cells were co-cultured, and PBS containing anti-human CD3 antibodies, anti-human CD28 antibodies, recombinant human IL-2 and anti-PD-1 antibodies was added;
  • Tumor cells + T cells (Ab + RP215 + ⁇ Sig-7) group: tumor cells and unactivated T cells were co-cultured, and anti-human CD3 antibodies, anti-human CD28 antibodies, recombinant human IL-2 and RP215 (final concentration 5 ⁇ g/ ml) anti-Siglec-7 antibody (final concentration 5 ⁇ g/ml) in PBS;
  • Tumor cells + T cells (Ab + ⁇ PD-1 + ⁇ Sig-7) group: tumor cells and unactivated T cells were co-cultured, and anti-human CD3 antibodies, anti-human CD28 antibodies, recombinant human IL-2 and anti-Siglec-7 were added Antibody (final concentration 5 ⁇ g/ml), anti-PD-1 antibody (final concentration 5 ⁇ g/ml) in PBS;
  • Tumor cells + T cells (Ab + mIgG) group tumor cells and unactivated T cells were co-cultured, and anti-human CD3 antibodies, anti-human CD28 antibodies, recombinant human IL-2 and mouse IgG were added (final concentration 10 ⁇ g/ml) of PBS as isotype control.
  • the volume of PBS system, the number of tumor cells, and the number of unactivated T cells were the same in each group.
  • the corresponding final concentrations of anti-human CD3 antibody, anti-human CD28 antibody, and recombinant human IL-2 added to each group were: 3 ⁇ g/ml, 1 ⁇ g/ml, and 30 U/ml, respectively.
  • Mononuclear cells were sorted from the ascites of ovarian cancer patients, and the ovarian cancer cell line OAC-E was monoclonally established for in vivo animal experiments.
  • T cells isolated from ovarian cancer ascites and human IL-2, anti-human CD3 antibody, and anti-human CD28 antibody, the External culture and activation to obtain activated T cells.
  • mice The tumor-forming mice were randomly divided into three groups, with 6 mice in each group:
  • PBS group Inject PBS, 40 ⁇ l around each tumor
  • T cells + goat IgG Inject activated T cells with goat IgG at a final concentration of 20 ⁇ g/mL and a dose of 40 ⁇ l per tumor per tumor; 5 ⁇ 10 5 T cells per tumor per tumor;
  • T cells + anti-Siglec-7 Inject activated T cells with goat anti-Siglec-7 antibody at a final concentration of 20 ⁇ g/mL and a dose of 40 ⁇ l per tumor per tumor, 5 ⁇ 10 5 per tumor per tumor T cells.
  • mice The three groups of mice were injected with the above drugs peritumorally for tumor treatment.
  • the drugs were injected subcutaneously once every 3 days, for a total of 8 injections.
  • the mouse tumor growth was measured in vivo every day and the tumor volume was calculated.
  • the mice were sacrificed, and the tumors were removed for measurement and statistics. The percentages of CD4 + T cells and CD8 + T cells in the ovarian cancer tumors of mice in each group were detected.
  • RP215 was used to block SIA-IgG and anti-Siglec-7 antibody was used to block Siglec-7 to culture activated T cells for experiments.
  • T cells isolated from ovarian cancer ascites are cultured and activated in vitro with human IL-2, anti-human CD3 antibody, and anti-human CD28 antibody to obtain activated T cells.
  • mice The tumor-forming mice were randomly divided into five groups, with 6 mice in each group:
  • PBS group Inject PBS, 40 ⁇ l around each tumor
  • RP215 group Inject the SIA-IgG blocking antibody RP215 with a final concentration of 20 ⁇ g/mL, 40 ⁇ l around each tumor;
  • T cell + mouse IgG group Inject activated T cells with mouse IgG at a final concentration of 20 ⁇ g/mL at a dose of 40 ⁇ l per tumor per tumor, and 3 ⁇ 10 5 T cells per tumor per tumor;
  • T cell + RP215 group Inject activated T cells with RP215 at a final concentration of 20 ⁇ g/mL at a dose of 40 ⁇ l per tumor per tumor, and 3 ⁇ 10 5 T cells per tumor per tumor;
  • T cell + anti-Siglec-7 group Inject activated T cells with a final concentration of 20 ⁇ g/mL and a dose of 40 ⁇ l around each tumor of mouse anti-Siglec-7 antibody, 3 ⁇ 10 per tumor per tumor 5 T cells.
  • the results of the 3.1 nude mouse tumor formation experiment suggest that peritumoral injection of activated T cells itself has anti-tumor effects. Therefore, the dosage and frequency of activated T cells were reduced in this experiment, with a total of 7 injections, 3 on each side each time. ⁇ 10 5 cells (A in Figure 12).
  • the mouse tumor growth was measured in vivo every day and the tumor volume was calculated.
  • the mice were sacrificed, and the tumors were removed for measurement and statistics.
  • the percentages of CD4 + T cells and CD8 + T cells in the ovarian cancer tumors of mice in each group were detected.
  • mice anti-Siglec-7 blocking monoclonal antibody was used for the experiment, and mouse IgG was used to culture T cells as a control.
  • the T cell treatment group had obvious necrosis.
  • the RP215 cultured T cell group had cell lysis holes, and the Siglec-7 cultured T cell group showed more obvious necrosis. of tumor necrosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La divulgation concerne l'utilisation d'une combinaison d'un lymphocyte T activé et d'un anticorps bloquant dans la préparation d'un médicament antitumoral, ainsi que le médicament antitumoral. Le lymphocyte T activé est obtenu par : séparation de lymphocytes T du tissu ou du fluide corporel d'un patient, réalisation d'un tri avec un anticorps anti-CD3 humain pour obtenir un lymphocyte CD3+T, puis réalisation d'une stimulation en vue d'une activation avec l'anticorps anti-CD3 humain, un anticorps anti-CD28 humain et de l'IL-2 humaine. L'anticorps de blocage est un ou plusieurs anticorps parmi un anticorps anti-SIA-IgG, un anticorps anti-Siglec-7, un anticorps anti-Siglec-9, un anticorps anti-Siglec-10 et un anticorps anti-PD-1. La combinaison est bien plus efficace en traitement que le lymphocyte T activé ou l'anticorps de blocage seuls, indiquant qu'il existe une synergie entre l'anticorps de blocage et le lymphocyte T activé, de sorte qu'un meilleur effet antitumoral est obtenu.
PCT/CN2023/092933 2022-06-28 2023-05-09 Utilisation d'une combinaison d'un lymphocyte t activé et d'un anticorps bloquant dans la préparation d'un médicament antitumoral, et médicament antitumoral WO2024001530A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210738566.9 2022-06-28
CN202210738566.9A CN114796483B (zh) 2022-06-28 2022-06-28 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物

Publications (1)

Publication Number Publication Date
WO2024001530A1 true WO2024001530A1 (fr) 2024-01-04

Family

ID=82522678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/092933 WO2024001530A1 (fr) 2022-06-28 2023-05-09 Utilisation d'une combinaison d'un lymphocyte t activé et d'un anticorps bloquant dans la préparation d'un médicament antitumoral, et médicament antitumoral

Country Status (2)

Country Link
CN (1) CN114796483B (fr)
WO (1) WO2024001530A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796483B (zh) * 2022-06-28 2022-11-08 北京大学 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106729705A (zh) * 2017-01-23 2017-05-31 河南省华隆生物技术有限公司 一种药物组合物及其应用
CN106834228A (zh) * 2017-01-17 2017-06-13 上海市公共卫生临床中心 一种体外扩增cd8+t细胞及其细胞亚群的方法
CN108699158A (zh) * 2016-03-08 2018-10-23 依奈特制药公司 Siglec中和抗体
CN109789206A (zh) * 2016-09-16 2019-05-21 生态有限公司 抗体和检查点抑制剂的组合疗法
CN110540960A (zh) * 2019-09-11 2019-12-06 苏州大学 结合有免疫检查点阻断剂的t淋巴细胞及其在制备抗肿瘤药物中的应用
CN110713978A (zh) * 2019-11-16 2020-01-21 福建省肿瘤医院（福建省肿瘤研究所、福建省癌症防治中心） 一种肿瘤抗原特异性肿瘤浸润性t细胞的分离方法
CN113913385A (zh) * 2021-09-01 2022-01-11 苏州璞惠卓越生物科技有限公司 一种抑制蛋白阻断型嵌合抗原受体修饰的免疫细胞及其用途
CN114031688A (zh) * 2022-01-06 2022-02-11 北京大学 一种人源化抗体及其应用
CN114796483A (zh) * 2022-06-28 2022-07-29 北京大学 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2939084T3 (es) * 2015-07-29 2023-04-18 Onk Therapeutics Ltd Células asesinas naturales y líneas de células asesinas naturales modificadas que tienen citotoxicidad aumentada

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108699158A (zh) * 2016-03-08 2018-10-23 依奈特制药公司 Siglec中和抗体
CN109789206A (zh) * 2016-09-16 2019-05-21 生态有限公司 抗体和检查点抑制剂的组合疗法
CN106834228A (zh) * 2017-01-17 2017-06-13 上海市公共卫生临床中心 一种体外扩增cd8+t细胞及其细胞亚群的方法
CN106729705A (zh) * 2017-01-23 2017-05-31 河南省华隆生物技术有限公司 一种药物组合物及其应用
CN110540960A (zh) * 2019-09-11 2019-12-06 苏州大学 结合有免疫检查点阻断剂的t淋巴细胞及其在制备抗肿瘤药物中的应用
CN110713978A (zh) * 2019-11-16 2020-01-21 福建省肿瘤医院（福建省肿瘤研究所、福建省癌症防治中心） 一种肿瘤抗原特异性肿瘤浸润性t细胞的分离方法
CN113913385A (zh) * 2021-09-01 2022-01-11 苏州璞惠卓越生物科技有限公司 一种抑制蛋白阻断型嵌合抗原受体修饰的免疫细胞及其用途
CN114031688A (zh) * 2022-01-06 2022-02-11 北京大学 一种人源化抗体及其应用
CN114796483A (zh) * 2022-06-28 2022-07-29 北京大学 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IBARLUCEA-BENITEZ ITZIAR, WEITZENFELD POLINA, SMITH PATRICK, RAVETCH JEFFREY V.: "Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 118, no. 26, 29 June 2021 (2021-06-29), pages e2107424118, XP093122065, ISSN: 0027-8424, DOI: 10.1073/pnas.2107424118 *
LIM JACKWEE, SARI-AK DUYGU, BAGGA TANAYA: "Siglecs as Therapeutic Targets in Cancer", BIOLOGY, MDPI, CH, vol. 10, no. 11, 13 November 2021 (2021-11-13), CH , pages 1178, XP093122064, ISSN: 2079-7737, DOI: 10.3390/biology10111178 *

Also Published As

Publication number Publication date
CN114796483B (zh) 2022-11-08
CN114796483A (zh) 2022-07-29

Similar Documents

Publication Publication Date Title
Ohno et al. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts
Zhang et al. Low-dose gemcitabine treatment enhances immunogenicity and natural killer cell-driven tumor immunity in lung cancer
CN106661129A (zh) 对ssea4抗原具有特异性的嵌合抗原受体
WO2019170147A1 (fr) Méthode et composition de traitement de tumeurs
WO2024001530A1 (fr) Utilisation d'une combinaison d'un lymphocyte t activé et d'un anticorps bloquant dans la préparation d'un médicament antitumoral, et médicament antitumoral
WO2018229163A1 (fr) Méthodes d'activation des lymphocytes t v delta 2 négatifs gamma delta
Story et al. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia
CN112930199A (zh) 免疫效应细胞治疗肿瘤的方法
WO2022222846A1 (fr) Récepteur antigénique chimérique ciblant cd19, son procédé de préparation et son utilisation
Xie et al. Preparation of highly activated natural killer cells for advanced lung cancer therapy
US20200095304A1 (en) Non-antibody binding proteins binding to pd-1 receptors and uses thereof
Dobrzanski et al. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival
CN117210411A (zh) 一种免疫细胞及其表达载体、应用和制备方法
CN111298111A (zh) 一种治疗和/或预防癌症的药物和应用
CN117045801A (zh) m6A RNA甲基化酶抑制剂与免疫检查点抑制剂联合治疗肿瘤
TW202039540A (zh) 一種治療ｅｂｖ相關性癌症之抗ｌｍｐ２ ｔｃｒ-ｔ細胞療法
WO2022171195A1 (fr) Traitement du cancer gastrique à l'aide d'un anticorps anti-cd87 en combinaison avec un anticorps anti-pd1
WO2021006316A1 (fr) Marqueur spécifique permettant d'identifier des cellules t attaquant spécifiquement des cellules cancéreuses
Lindsay et al. NK cells reduce anergic T cell development in early-stage tumors by promoting myeloid cell maturation
CN115960257B (zh) 靶向IL13Rα2的经优化的嵌合抗原受体及其用途
Xu et al. Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate
US20230406949A1 (en) Combinatorial immunotherapeutic methods and compositions for pancreatic ductal adenocarcinoma treatment
CN109793889B (zh) 一种肿瘤疫苗及其制备方法
EP4052716A1 (fr) Thérapie contre le cancer impliquant des lymphocytes t modifiés par un récepteur antigénique chimérique (car) et le parvovirus h-1
Decock et al. OPEN ACCESS EDITED BY

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23829716

Country of ref document: EP

Kind code of ref document: A1